{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:39:59Z","timestamp":1758814799724},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/cad.0000000000000042","type":"journal-article","created":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T09:07:25Z","timestamp":1383296845000},"page":"340-345","source":"Crossref","is-referenced-by-count":9,"title":["The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients"],"prefix":"10.1097","volume":"25","author":[{"given":"Tamar","family":"Safra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noam","family":"Asna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat","family":"Veizman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shulem","family":"Shpigel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianna","family":"Matcejevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Inbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Grisaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R3-12-20210203","first-page":"25","article-title":"Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.","volume":"3","author":"Mantia-Smaldone","year":"2011","journal-title":"Cancer Manag Res"},{"key":"R6-12-20210203","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"R7-12-20210203","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","article-title":"Phase II study of gemcitabine (2,2-difluorodeoxycytidine) in previously treated ovarian cancer patients.","volume":"86","author":"Lund","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"R8-12-20210203","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","article-title":"Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.","volume":"16","author":"Rose","year":"1998","journal-title":"J Clin Oncol"},{"key":"R10-12-20210203","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/0003-4819-111-4-273","article-title":"Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.","volume":"111","author":"McGuire","year":"1989","journal-title":"Ann Intern Med"},{"key":"R11-12-20210203","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (taxol).","volume":"332","author":"Rowinsky","year":"1995","journal-title":"N Engl J Med"},{"key":"R12-12-20210203","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2165\/11591720-000000000-00000","article-title":"Management strategies for recurrent platinum-resistant ovarian cancer.","volume":"71","author":"Naumann","year":"2011","journal-title":"Drugs"},{"key":"R13-12-20210203","first-page":"11","article-title":"Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.","volume":"22","author":"Heinemann","year":"1995","journal-title":"Semin Oncol"},{"key":"R14-12-20210203","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","article-title":"Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.","volume":"63","author":"Shapiro","year":"1996","journal-title":"Gynecol Oncol"},{"key":"R16-12-20210203","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00000421-199910000-00005","article-title":"Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum.","volume":"22","author":"Silver","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"R17-12-20210203","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1023\/A:1008364327684","article-title":"Phase II study of gemcitabine in ovarian cancer.","volume":"10","author":"Von Minckwitz","year":"1999","journal-title":"Ann Oncol"},{"key":"R20-12-20210203","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0090-8258(03)00399-8","article-title":"Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.","volume":"90","author":"Markman","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R21-12-20210203","first-page":"72","article-title":"Interaction between cisplatin and gemcitabine in vitro and in vivo.","volume":"22","author":"Peters","year":"1995","journal-title":"Semin Oncol"},{"key":"R22-12-20210203","first-page":"521","article-title":"Synergistic interaction between cisplatin and gemcitabine in vitro.","volume":"2","author":"Bergman","year":"1996","journal-title":"Clin Cancer Res"},{"key":"R25-12-20210203","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/mol.63.4.862","article-title":"Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines.","volume":"63","author":"Moufarij","year":"2003","journal-title":"Mol Pharmacol"},{"key":"R26-12-20210203","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2007.02.001","article-title":"Mechanisms of resistance to cisplatin and carboplatin.","volume":"63","author":"Stewart","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"R27-12-20210203","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0079-6603(01)67026-0","article-title":"Cisplatin: from DNA damage to cancer chemotherapy.","volume":"67","author":"Cohen","year":"2001","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"R28-12-20210203","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/bi00361a026","article-title":"Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA.","volume":"25","author":"Eastman","year":"1986","journal-title":"Biochemistry"},{"key":"R30-12-20210203","first-page":"567","article-title":"Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2,2-difluorodeoxycytidine.","volume":"38","author":"Heinemann","year":"1990","journal-title":"Mol Pharmacol"},{"key":"R32-12-20210203","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ygyno.2006.03.018","article-title":"Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group.","volume":"103","author":"Brewer","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R35-12-20210203","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/gyno.2002.6850","article-title":"Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R36-12-20210203","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/00001813-199510000-00010","article-title":"In vitro activity of titanocenedichloride versus cisplatin in four ovarian carcinoma cell lines evaluated by a microtiter plate ATP bioluminescence assay.","volume":"6","author":"Kurbacher","year":"1995","journal-title":"Anticancer Drugs"},{"key":"R37-12-20210203","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1985.3.7.925","article-title":"Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity.","volume":"3","author":"Markman","year":"1985","journal-title":"J Clin Oncol"},{"key":"R38-12-20210203","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/13543784.2012.666236","article-title":"Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.","volume":"21","author":"Muggia","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"R41-12-20210203","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00001813-200306000-00003","article-title":"Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer.","volume":"14","author":"Breidenbach","year":"2003","journal-title":"Anticancer Drugs"},{"key":"R43-12-20210203","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/CAD.0b013e3281de727e","article-title":"A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physicians choice in patients with recurrent platinum-resistant ovarian cancer.","volume":"18","author":"Cree","year":"2007","journal-title":"Anticancer Drugs"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0000000000000042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:01:18Z","timestamp":1620946878000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-201403000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0000000000000042","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}